Here, we report the isolation of multidrug resistant S. Paratyphi A producing CTX-M-15-type extended-spectrum beta-lactamase (ESBL) from a traveller returning from India. To our knowledge, this is the first report of S. Paratyphi A with CTX-M-15-type ESBL isolated from a human. Enteric fever, including typhoid fever caused by S. enterica serotype Typhi (S. Typhi) and paratyphoid fever caused by S. enterica serotype Paratyphi A (S. Paratyphi A), is one of the most important febrile illnesses in tropical and subtropical countries, with high rates of morbidity and mortality [1] . In industrialised countries, enteric fever is a common cause of fever in returned travellers [2] . The emergence of drugresistance in S. Typhi and S. Paratyphi A is an emerging public health problem. Owing to the recent increase of fluoroquinolone resistance, third-generation cephalosporins, such as ceftriaxone or cefotaxime, have become the primary drugs for treatment of enteric fever [3] .
Case report
In July 2013, a Japanese woman in her mid-20s was admitted to a hospital in Manali, India for fever over 38.5 ºC, diarrhoea, and anorexia, where she was diagnosed with typhoid fever based on clinical symptoms and a non-specified rapid serological test. She had been in India for five weeks prior to the admission. Before her visit to India, she had been on a seven-week trip to China, Myanmar, Thailand, and Nepal. She was treated with parenteral cephalosporin for three days.
No further details on the treatment regimen in India were available. The patient returned to Japan on day 4 of illness owing to sustained fever, diarrhoea, and anorexia. During her travel from India to Japan (days 5-7), the patient took oral combined ofloxacin-cefixime. On day 7, she was admitted to our hospital with diarrhoea and anorexia but without fever. On examination, deep palpation of the lower abdominal area caused mild discomfort, otherwise, physical examination was normal. She did not have any underlying illness, and was not on any regular medication. Eight months prior to the admission at the hospital in India she had been vaccinated against Salmonella Typhi (Vi polysaccharide).
Laboratory analyses
On admission, stool and blood samples were taken for culture. Antimicrobial susceptibility test was performed by broth microdilution in accordance with the Clinical and Laboratory Standards Institutes [4] . The patient's stool was screened on admission for meticillin-resistant Staphylococcus aureus, vancomycinresistant Enterococci, and Gram-negative rods resistant to one or multiple agents in the extended-spectrum cephalosporin class and/or that demonstrated elevated minimum inhibitory concentrations (MICs) (>1 mg/L) to imipenem and/or meropenem. Screening culture of stool was positive only for drug-sensitive Escherichia coli and Enterobacteriaceae spp.
Results from blood cultures were positive for S. Paratyphi A two days after admission and S. Paratyphi A was found to be resistant to cefotaxime (MIC = 64 mg/L) and ceftazidime (MIC > 16 mg/L). Addition of clavulanic acid to each cephalosporin lowered the MIC to 0.25 mg/L and 1 mg/L, respectively. This isolate was also resistant to nalidixic acid, and categorised as intermediate to ciprofloxacin (Table) . Due to the atypical susceptibility pattern and the requirement for the verification susceptibility test process, it took longer than one week for the final susceptibility result to be available.
The presence of the gene conferring the ESBL phenotype was verified by polymerase chain reaction (PCR) as described elsewhere [5] . Sequencing of the PCR products revealed that S. Paratyphi A was positive for bla CTX-M-15 . The presence of the plasmid-mediated quinolone resistance genes including qnrA, qnrB, qnrC, qnrS, and aac(6')-Ib was investigated using PCR described elsewhere [6] [7] [8] [9] . However plasmid-mediated quinolone resistance genes were not detected in this isolate.
Patient treatment and outcome
Upon admission, we treated the patient with ceftriaxone (2 g per day for 8 days), and the patient's symptoms resolved after eight days of admission. After the final susceptibility results were available, the initial antibiotic treatment was changed on day 9 from ceftriaxone to azithromycin (orally, 500 mg per day), which was administered for seven days. A stool culture obtained on admission was negative for S. Paratyphi A. Stool cultures repeated before changing antibiotic treatment as well as eight, nine, and 10 days after completing azithromycin treatment also remained negative for S. Paratyphi A. The patient was discharged on 10 days after admission.
Discussion and conclusion
Although ESBL-producing organisms are emerging among Enterobacteriaceae, ESBL-producing S. Typhi or S. Paratyphi A have been reported rarely in Nepal and the Middle East [10, 11] ; CTX-M-15 type ESBL-producing S. Typhi were previously reported in patients in Middle Eastern countries [11, 12] .
bla CTX-M-15 genes have been identified worldwide in Enterobacteriaceae; further, isolation of these genes from Escherichia coli has been reported to be increasing [13] . The acquisition of bla CTX-M-15 as a transferable plasmid from another enteric bacterium has previously been reported in S. Typhi [5] .
Of particular concern are reports of increasing isolation rates of S. Paratyphi A from India and other parts of Asia [14] , which might be attributed to use of protective vaccines (Vi polysaccharide and live oral Ty21a) effective against S. Typhi, but not S. Paratyphi A [14] .
The number of reports on ESBL in S. Typhi and S. Paratyphi A is still limited, and thus, extendedspectrum cephalosporins would still be a reasonable empiric treatment for a suspected case of enteric fever in the current situation. The patient improved on day 8 before antibiotics were changed 
